KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EPS (Weighted Average and Diluted) (2019 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with $1.51 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 1178.57% year-over-year to $1.51; the TTM value through Mar 2026 reached $3.66, up 304.47%, while the annual FY2025 figure was $2.33, 206.88% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $1.51 in Q1 2026 for Alnylam Pharmaceuticals, up from $0.82 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.84 in Q3 2025 and bottomed at -$3.32 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.68, with a median of -$0.65 recorded in 2024.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 292.31% in 2025 and then surged 1178.57% in 2026.
  • Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.68 in 2022, then surged by 35.12% to -$1.09 in 2023, then soared by 40.37% to -$0.65 in 2024, then skyrocketed by 226.15% to $0.82 in 2025, then skyrocketed by 84.15% to $1.51 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $1.51, $0.82, and $1.84 for Q1 2026, Q4 2025, and Q3 2025 respectively.